Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05493553 · ClinicalTrials.gov registry record · NA

Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability

A NA study of Healthy and Impaired Glucose Tolerance, sponsored by Unicity International.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05493553 is a NA study of Healthy and Impaired Glucose Tolerance that has completed, run by Unicity International. The registered enrollment target is 50 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05493553, a NA study of Healthy and Impaired Glucose Tolerance, has completed, sponsored by Unicity International.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the short-term effect of a nutritional program consisting of a yerba mate supplement, fiber supplement, and intermittent fasting on glycemic variability in men and women with risk factors for impaired fasting glucose.

Interventions

  • DIETARY_SUPPLEMENT Dietary supplement regimen
  • OTHER Dietary supplement and intermittent fasting regimen

Study Locations (1)

Illinois

  • Biofortis Clinical Research - Addison

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-08-08
Est. Completion 2022-09-29
Phase NA

Sponsor

Unicity International

1 total trials

What the Registry Record Tells You About NCT05493553

The ClinicalTrials.gov registry entry for NCT05493553 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The listed sponsor is Unicity International, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Dietary supplement regimen is the first listed.

NCT05493553 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05493553 about?

NCT05493553 is a clinical study titled "Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability". The purpose of this study is to determine the short-term effect of a nutritional program consisting of a yerba mate supplement, fiber supplement, and intermittent fasting on glycemic variability in men and women with risk factors for impaired fasting glucose.

What is the current status of trial NCT05493553?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2022-08-08. Estimated completion is 2022-09-29.

What conditions does trial NCT05493553 study?

This clinical trial studies the following conditions: Healthy, Impaired Glucose Tolerance.

What interventions are being tested in trial NCT05493553?

The interventions under investigation include: Dietary supplement regimen (DIETARY_SUPPLEMENT), Dietary supplement and intermittent fasting regimen (OTHER).

Who is sponsoring clinical trial NCT05493553?

This trial is sponsored by Unicity International, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05493553 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.